MA56203A - Anticorps humains dirigés contre la protéine morphogénétique osseuse 6 - Google Patents

Anticorps humains dirigés contre la protéine morphogénétique osseuse 6

Info

Publication number
MA56203A
MA56203A MA056203A MA56203A MA56203A MA 56203 A MA56203 A MA 56203A MA 056203 A MA056203 A MA 056203A MA 56203 A MA56203 A MA 56203A MA 56203 A MA56203 A MA 56203A
Authority
MA
Morocco
Prior art keywords
human antibodies
antibodies against
bone morphogenetic
morphogenetic protein
against bone
Prior art date
Application number
MA056203A
Other languages
English (en)
Inventor
Sarah J Hatsell
Vincent J Idone
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA56203A publication Critical patent/MA56203A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056203A 2019-06-12 2020-06-09 Anticorps humains dirigés contre la protéine morphogénétique osseuse 6 MA56203A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962860597P 2019-06-12 2019-06-12

Publications (1)

Publication Number Publication Date
MA56203A true MA56203A (fr) 2022-04-20

Family

ID=71944214

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056203A MA56203A (fr) 2019-06-12 2020-06-09 Anticorps humains dirigés contre la protéine morphogénétique osseuse 6

Country Status (7)

Country Link
US (1) US20220251184A1 (fr)
EP (1) EP3983436A1 (fr)
JP (1) JP2022537142A (fr)
AU (1) AU2020292246A1 (fr)
CA (1) CA3141266A1 (fr)
MA (1) MA56203A (fr)
WO (1) WO2020251924A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (fr) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions et procedes destines au traitement du cancer
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
PT2644594T (pt) 2007-09-28 2017-11-20 Pfizer Direcionamento a células cancerosas utilizando nanopartículas
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
AU2016211890B2 (en) * 2008-11-13 2018-03-22 The General Hospital Corporation Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) * 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6

Also Published As

Publication number Publication date
JP2022537142A (ja) 2022-08-24
AU2020292246A1 (en) 2022-01-27
WO2020251924A1 (fr) 2020-12-17
EP3983436A1 (fr) 2022-04-20
CA3141266A1 (fr) 2020-12-17
US20220251184A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
MA43576A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
CY1124143T1 (el) Οστικες μορφογενετικες πρωτεϊνες
MA51903A (fr) Formulations d'anticorps b7-h4
SG11202107978RA (en) Methods and system for the reconstruction of drug response and disease networks and uses thereof
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l'adn
SG11202109277WA (en) Stable protein formulations
ZA201805721B (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3764798A4 (fr) Protéines insecticides issues de plantes et procédés pour leur utilisation
DK3914194T3 (da) Hemi-artroplastik-knogleledsimplantat
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
EP3648769A4 (fr) N-acyl amides dérivés du microbiote humain pour le traitement d'une maladie humaine
FR3003173B1 (fr) Substituts osseux greffes par des peptides mimetiques de la proteine humaine bmp-2.
ZA202100092B (en) Modified cas9 protein and use thereof
CY1114811T1 (el) Νεα κλασματα πρωτεϊνων γαλακτος και η χρηση τους για την προληψη ή τη θεραπεια των χρονιων φλεγμονωδων νοσων
MA55033A (fr) Formulation d'anticorps thérapeutique
ZA202109744B (en) Anti-connective tissue growth factor antibody and application thereof
MA54097A (fr) Anticorps anti-fn14 humain
MA56203A (fr) Anticorps humains dirigés contre la protéine morphogénétique osseuse 6
IL284208A (en) Antibody formulations that bind human cd137 and their uses
IL281397B (en) Human pd–l1 antibodies
MA55761A (fr) Formulations et anticorps anti-cd38